CD8A and neoplasm: Blockade of the CXCL12 receptor CXCR4 with AMD3100 had significant anti-tumor activity and reversed the pro-angiogenic activity of Bay60-6583, but not its effects on MDSC accumulation and tumor-infiltrating Treg or CD8+T cells number.